Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Spectrochim Acta A Mol Biomol Spectrosc ; 309: 123823, 2024 Mar 15.
Article in English | MEDLINE | ID: mdl-38181621

ABSTRACT

In this work, a green, fast, and simple synchronous spectrofluorimetric approach has been developed to simultaneously determine favipiravir, levodropropizine, and moxifloxacin hydrochloride as co-administered medications for COVID-19 treatment in pure form and spiked human plasma. The synchronous fluorescence spectroscopy technique to analyze the studied drugs at Δλ = 110 nm enabled the determination of levodropropizine at 360 nm. Then, applying Fourier Self-Deconvolution to each spectra to measure favipiravir and moxifloxacin hydrochloride at peak amplitudes of 431 nm and 479 nm, respectively, without any interference. Favipiravir, levodropropizine, and moxifloxacin hydrochloride could be sensitively determined using the described approach over concentration ranges of 20-300 ng/mL, 10-600 ng/mL, and 50-500 ng/mL, respectively. The method's validation was carried out effectively in accordance with guidelines recommended by the ICH. Finally, the Eco-scale and Green Analytical Procedure Index (GAPI) techniques have been used to evaluate the greenness of the proposed method.


Subject(s)
Amides , COVID-19 Drug Treatment , COVID-19 , Propylene Glycols , Pyrazines , Humans , Moxifloxacin , Spectrometry, Fluorescence
2.
Drug Des Devel Ther ; 15: 3937-3952, 2021.
Article in English | MEDLINE | ID: mdl-34556975

ABSTRACT

BACKGROUND/OBJECTIVE: Periodontitis is a widely spread oral infection and various antibiotics are utilized for its treatment, but high oral doses and development of antibiotic resistance limit their use. This study was aimed at development of natural polymer-based mucoadhesive bilayer films loaded with moxifloxacin hydrochloride (Mox) and clove essential oil (CEO) to potentially combat bacterial infection associated with periodontitis. METHODS: Films were synthesized by double solvent casting technique having an antibiotic in the gellan gum-based primary layer with clove oil in a hydroxyethyl cellulose-based secondary layer. RESULTS: Prepared films were transparent, flexible, and showed high antibacterial response against both gram-positive and gram-negative bacteria. The films showed excellent pharmaceutical attributes in terms of drug content, folding endurance, swelling index, and mucoadhesive strength. Solid state characterization of formulation showed successful incorporation of drug and oil in separate layers of hydrogel structure. An in-vitro release study showed an initial burst release of drug followed by sustained release for up to 48 hours. CONCLUSION: The prepared mucoadhesive bilayer buccal films could be used as a potential therapeutic option for the management of periodontitis.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clove Oil/pharmacology , Moxifloxacin/pharmacology , Polysaccharides, Bacterial/chemistry , Adhesiveness , Administration, Buccal , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/chemistry , Chemistry, Pharmaceutical/methods , Clove Oil/administration & dosage , Delayed-Action Preparations , Drug Liberation , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Moxifloxacin/administration & dosage , Moxifloxacin/chemistry , Oils, Volatile/administration & dosage , Oils, Volatile/pharmacology , Periodontitis/drug therapy , Periodontitis/microbiology
3.
Int J Pharm ; 602: 120662, 2021 Jun 01.
Article in English | MEDLINE | ID: mdl-33933641

ABSTRACT

High local intraosseous levels of antimicrobial agents are required for adequate long-term treatment of chronic osteomyelitis (OM). In this study, biodegradable composite scaffolds of poly-lactide-co-ε-caprolactone/calcium phosphate (CaP) were in-situ synthesized using two different polymer grades and synthesis pathways and compared to composites prepared by pre-formed (commercially available) CaP for delivery of the antibiotic moxifloxacin hydrochloride (MOX). Phase identification and characterization by Fourier transform infra-red (FTIR) spectroscopy, X-ray powder diffraction (XRPD) and scanning electron microscope (SEM) confirmed the successful formation of different CaP phases within the biodegradable polymer matrix. The selected in-situ formed CaP scaffold showed a sustained release for MOX for six weeks and adequate porosity. Cell viability study on MG-63 osteoblast-like cells revealed that the selected composite scaffold maintained the cellular proliferation and differentiation. Moreover, it was able to diminish the bacterial load, inflammation and sequestrum formation in the bones of OM-induced animals. The results of the present work deduce that the selected in-situ formed CaP composite scaffold is a propitious candidate for OM treatment, and further clinical experiments are recommended.


Subject(s)
Osteomyelitis , Polyesters , Animals , Caproates , Dioxanes , Lactones , Moxifloxacin , Osteomyelitis/drug therapy , Tissue Engineering , Tissue Scaffolds
4.
Carbohydr Polym ; 244: 116482, 2020 Sep 15.
Article in English | MEDLINE | ID: mdl-32536391

ABSTRACT

Osteomyelitis is a progressive inflammatory disease requiring prolonged systemic treatment with high antibiotic doses, and is very challenging to be treated. The use of locally applied antibiotics loaded on a biodegradable carrier at surgery sites is hypothesized to prevent post-operative osteomyelitis, while providing site-specific drug release. In this work, chitosan-based calcium phosphate composites were prepared and loaded with moxifloxacin hydrochloride. The in-situ formation of calcium phosphates within the composite was experimentally confirmed by Fourier transform infra-red spectroscopy, X-ray powder diffraction, and scanning electron microscopy. Results showed that the composites provided complete drug release over three days, and the selected composite formulation induced differentiation and proliferation of osteoblasts, while reducing bacterial count, inflammation and intra-medullary fibrosis in bone tissue specimens of osteomyelitis-induced animal model. Hence, we can conclude that the in situ prepared antibiotic-loaded calcium phosphate chitosan composite is promising in preventing post-operative osteomyelitis, and is worthy of clinical experimentation.


Subject(s)
Biocompatible Materials/therapeutic use , Drug Carriers/chemistry , Moxifloxacin/administration & dosage , Osteomyelitis/drug therapy , Tissue Scaffolds , Animals , Anti-Bacterial Agents/administration & dosage , Calcium Phosphates/chemistry , Cell Line , Chitosan/chemistry , Humans , Osteoblasts , Rabbits
5.
Int J Pharm ; 457(1): 206-13, 2013 Nov 30.
Article in English | MEDLINE | ID: mdl-24096301

ABSTRACT

We report a simple method to fabricate multifunctional polyelectrolyte thin films to load and deliver the therapeutic drugs. The multilayer thin films were assembled by the electrostatic adsorption of poly (allylamine hydrochloride) (PAH) and dextran sulfate (DS). The silver nanoparticles (Ag NPs) biosynthesized from novel Hybanthus enneaspermus leaf extract as the reducing agent were successfully incorporated into the film. The biosynthesized Ag NPs showed excellent antimicrobial activity against the range of enteropathogens, which could be significantly enhanced when used with commercial antibiotics. The assembled silver nano composite multilayer films showed rupture and deformation when they are exposed to laser. The Ag NPs act as an energy absorption center, locally heat up the film and rupture it under laser treatment. The antibacterial drug, moxifloxacin hydrochloride (MH) was successfully loaded into the multilayer films. The total amount of MH release observed was about 63% which increased to 85% when subjected to laser light exposure. Thus, the polyelectrolyte thin film reported in our study has significant potential in the field of remote activated drug delivery, antibacterial coatings and wound dressings.


Subject(s)
Anti-Bacterial Agents/chemistry , Aza Compounds/chemistry , Drug Delivery Systems , Metal Nanoparticles/chemistry , Quinolines/chemistry , Silver/chemistry , Violaceae , Amoxicillin-Potassium Clavulanate Combination/chemistry , Amoxicillin-Potassium Clavulanate Combination/pharmacology , Anti-Bacterial Agents/pharmacology , Aza Compounds/pharmacology , Bacteria/drug effects , Dextran Sulfate/chemistry , Erythromycin/chemistry , Erythromycin/pharmacology , Fluoroquinolones , Lasers , Moxifloxacin , Plant Extracts/chemistry , Plant Leaves , Polyamines/chemistry , Quinolines/pharmacology , Silver/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL